What question did this study set out to answer?

To evaluate the effectiveness of insulin-sensitising drugs on reproductive outcomes in women with polycystic ovary syndrome (PCOS).

May 10, 2012Open Access

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

Key Points

To evaluate the effectiveness of insulin-sensitising drugs on reproductive outcomes in women with polycystic ovary syndrome (PCOS).
Review of existing studies on metformin, rosiglitazone, pioglitazone, and D-chiro-inositol
Comparison of reproductive outcomes between insulin-sensitising drugs and clomiphene
Evaluation of clinical pregnancy and live birth rates
Metformin improved clinical pregnancy rates but did not significantly increase live birth rates
No advantage of metformin when used alone or with clomiphene
Limited role of metformin in enhancing reproductive outcomes in PCOS

Abstract

In agreement with the previous review, metformin was associated with improved clinical pregnancy but there was no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene. Therefore, the role of metformin in improving reproductive outcomes in women with PCOS appears to be limited.

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

Key Points

Abstract

Cite This Study